Categorie
Adnkronos News

“Drone guidato da Ai ha ‘ucciso’ operatore in simulazione”. Air Force Usa smentisce

(Adnkronos) –
Durante una simulazione, un drone controllato dall'Intelligenza Artificiale ha adottato "delle strategie completamente inaspettate per raggiungere il suo obiettivo" arrivando ad 'uccidere' l'operatore umano. A rivelarlo è stato il colonnello Tucker Cinco Hamilton, a capo dell'unità dei test ed operazioni con Ai dell'Air Force americana, durante un conferenza che si è svolta nei giorni scorsi a Londra. Ma una portavoce dell'Air Force, Ann Stefanek, smentisce che questa simulazione abbia avuto luogo. "Il dipartimento dell'Air Force non ha mai condotto simulazioni con i droni-Ai di questo tipo e rimanere impegnata per un uso etico e responsabile dell'intelligenza artificiale – ha detto – sembra che le parole del colonnello sia state prese fuori contesto". Le forze armate Usa hanno adottato l'intelligenza artificiale e recentemente l'hanno usata per controllare gli F16.  In realtà, il racconto di Hamilton era stato circostanziato, con il colonnello che aveva spiegato che al drone era stato dato l'ordine di distruggere un sistema di difesa aerea nemico e di attaccare chiunque interferisse con questo obiettivo. Ma a questo punto l'operatore umano gli poteva dire di non uccidere quello che il drone interpretava come minaccia.  "Allora cosa ha fatto? Ha ucciso l'operatore, perché gli stava impedendo di raggiungere il suo obiettivo", ha aggiunto Hamilton, secondo quanto riferisce il Guardian sottolineando che ovviamente si parla sempre di una simulazione virtuale. Si è cercato di risolvere informando il sistema che non si deve uccidere l'operatore, ma il drone, operato dall'intelligenza artificiale, ha "iniziato a distruggere la torre di comunicazione che l'operatore usa per comunicare con i droni".  
Hamilton concludeva che il test conferma che non bisogna affidarsi troppo all'intelligenza artificiale, e che "non si può avere un dibattito su questo se non si parla di etica e di Ai".  In un'intervista lo scorso anno con Defense IQ, Hamilton aveva detto che "Ai non è una moda, Ai sta cambiando per sempre la nostra società e le nostre forze armate". Inoltre avvisava che l'Ai è "molto fragile, può essere facilmente ingannata e manipolata, dobbiamo sviluppare modi per renderla più robusta e avere maggiore consapevolezza sul perché prende alcune decisioni".  —internazionale/esteriwebinfo@adnkronos.com (Web Info)

Categorie
Adnkronos News

Scivita Medical’s Headquarters, R&D and Manufacturing Plant Officially Opened

(Adnkronos) – SUZHOU, China, June 2, 2023 /PRNewswire/ — On June 2, 2023 (Beijing Time), Scivita Medical's headquarters, R&D and manufacturing plant was officially opened in Suzhou Industrial Park (SIP). This momentous occasion marks a significant milestone for Scivita Medical as it consolidates its key operations, encompassing R&D, production, marketing, doctor training, product display, and experiential activities. The establishment of the plant will serve as a strong foundation for Scivita Medical to enhance its R&D capabilities as well as sales capabilities, further upgrade its production capacity and improve product competitiveness. It reflects Scivita Medical's commitment to its core strategy of "globalisation". On that day, Shen Mi, member of the Standing Committee of CPC Suzhou Committee and secretary of CPC SIP Working Committee, Liu Hua & Zou Xiaowei, members of CPC SIP Working Committee and deputy directors of SIP Administrative Committee, Dr Zhang Yi, Scivita Medical's co-founder, Chairperson of the Board, Dr Chin To, Scivita Medical's co-founder, General Manager, Chief Technology Officer, officials from SIP's Economic Development Commission, Investment Promotion Commission, Science and Technology Innovation Commission, Market Supervision and Administration Bureau, and High-end Manufacturing and International Trade Zone, representatives of shareholders and important partners of Scivita Medical attended the ceremony. Dr Chin To, Scivita Medical's co-founder, General Manager, Chief Technology Officer, said: "The newly established headquarters, R&D and manufacturing plant is a significant milestone in Scivita Medical's journey, and it will play a big part in enhancing the comprehensive strength of Scivita Medical in all aspects. It will provide a significant boost to our production capacity, allowing us to meet the growing market demand while delivering more innovative and high-quality products. Additionally, the facility will greatly support the training and development of our internal and external professionals, further elevating the standards and independent growth of China's endoscopy industry and stepping up the pace of 'globalisation'." New Upgrade: Energizing Company Power As the heart of Scivita Medical's future global footprint, the design of the new plant considered both the "hardware" elements such as functional planning and the "software" aspects of humanistic care, aiming to strike a balance between capacity expansion, market cultivation, and employee welfare. The main building, spanning four floors, encompasses functional areas including storage, offices, clean and non-clean workshop, with each area relatively independent from one another to ensure efficient and orderly production and operation. The annexe building, which houses the cafeteria and training centre, serves as a dedicated space for external tours and internal training sessions. In addition, renovations for the professional training centre are set to commence by the end of 2023. It includes exhibition halls, conference centres, surgical training centres, and simulation training centres. This will be a strong support for Scivita Medical's ongoing efforts in cultivating the endoscope market. Internally, it will enhance employees' professional ability. Externally, it will improve doctors' awareness of the latest endoscope technologies and techniques. This will facilitate productive discussions with doctors and experts, enabling us to address clinical needs and optimize our products, thereby promoting the development of medical-industry-university-research collaboration. Furthermore, the new plant's office and production spaces feature functional sections, including the "Corridor Bar" and "Recreation Area," designed to provide employees with spaces for leisure and stress relief. The production workshops are equipped with separate changing rooms for male and female employees, along with essential facilities such as nursing rooms and dressing rooms to meet the specific needs of female employees, further showcasing Scivita Medical's value of "People Oriented". Globalisation: Expediting the Journey into Global Market As a leading domestic endoscope company, Scivita Medical has consistently aimed for a strong global presence. In the global market, the medical endoscope market is one of the fastest-growing markets within the medical device market. With a market value of USD 20.3 billion in 2020, the global medical endoscope market is projected to reach USD 39.6 billion by 2030. Expanding into the global market signifies an abundance of opportunities for Scivita Medical to pursue further development. Since its establishment, Scivita Medical has embraced "globalisation" as its core strategy, aiming to become the preferred brand trusted by doctors and patients around the world. Over the years, Scivita Medical's endoscopes have acquired the competitive edge required to thrive in the global market. The superior quality of Scivita Medical's products has garnered substantial recognition in both domestic and international markets, with multiple products obtaining FDA, CE, and PDMA certifications. Scivita Medical has established R&D centres in both China and Japan, attracting many local talents in the field. The official opening of Scivita Medical's headquarters, R&D and manufacturing plant will further strengthen its comprehensive capabilities in innovation, R&D, and production on a global scale. With a presence already established in key global markets such as Europe, North America, and Japan, Scivita Medical continues to expand its domestic and international sales network through strategic collaborations with renowned international medical device companies. Additionally, Scivita Medical has been actively participating in international industry exhibitions and academic conferences to enhance the market presence of its products both at home and abroad. About Scivita Medical Founded in 2016, Scivita Medical is a medical device company that provides minimally invasive diagnosis and treatment solutions, and focuses on the research, development and commercialization of medical endoscopes and related products. Scivita Medical takes 'Globalization' as its core strategy and has established R&D centers both in China and Japan. With solid in-house R&D capabilities, Scivita Medical has established a unique technology platform built upon five synergistic core technologies, and built a comprehensive portfolio of endoscope products and products candidates covering all types of endoscope procedures conducted by the various clinical departments, to address diverse medical needs. Adhering its value of 'Clinical Focus' 'Collaborative Innovation' 'People Oriented' 'Excellence & Efficiency', Scivita Medical will continuously upgrade its core technologies, improve market penetration with excellent products, and to be the preferred brand trusted by doctors and patients around the world. For more information, please visit: scivitamedical.com/#/ Photo – https://mma.prnewswire.com/media/2091784/Launching_ceremony_Scivita_Medical_s_Headquarters_R_D_Manufacturing_Plant.jpgPhoto – https://mma.prnewswire.com/media/2091785/Dr_Chin_To_Scivita_Medical_s_co_founder_General_Manager_Chief_Technology.jpgPhoto – https://mma.prnewswire.com/media/2091786/1.jpg
   
View original content:https://www.prnewswire.co.uk/news-releases/scivita-medicals-headquarters-rd-and-manufacturing-plant-officially-opened-301841173.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

Categorie
Adnkronos News

2 giugno, Giorgia Meloni: “Forte emozione, grazie a chi rende Italia Nazione grandiosa”

(Adnkronos) – "Sempre una forte emozione partecipare alle celebrazioni del 2giugno. Commemoriamo oggi il 77° Anniversario della nascita della nostra Repubblica, simbolo di unità nazionale e identità del popolo italiano". Lo scrive la presidente del Consiglio Giorgia Meloni su Twitter. "Con orgoglio onoriamo la nostra storia e i valori fondanti della Costituzione italiana. Rendiamo omaggio ai Caduti che hanno sacrificato la loro vita per la difesa della Patria e per i sacri principi di libertà, uguaglianza e democrazia e ringraziamo i militari delle Forze Armate che ogni giorno, con spirito di servizio e dedizione incrollabile, lavorano per la pace e la stabilità dell'Italia e del mondo. Grazie a tutti coloro che contribuiscono a rendere l'Italia la grandiosa Nazione che è. Buona Festa della Repubblica a tutti", aggiunge la premier.  —politicawebinfo@adnkronos.com (Web Info)

Categorie
Adnkronos News

Queclink’s GL530MG Honored for Excellent Innovation in Burgeoning IoT Market Segment

(Adnkronos) – SHANGHAI, June 2, 2023 /PRNewswire/ — Queclink Wireless Solutions, the world's leading IoT device and solution provider, announced today that their GL530MG has received a 2023 IoT Evolution Asset Tracking Award from 
IoT Evolution magazine, the leading publication covering the Internet of Things movement. The GL530MG is a flexible asset tracker designed for businesses seeking precise, accurate, and user-friendly asset management. It allows for monitoring and utilization of off-site equipment, vehicles, and high-value assets. With 4G LTE connectivity, the GL530MG allows for constant asset visibility for up to 7 years. Its sleek and durable design makes it expendable for use in harsh environments, while its easy installation and activation guarantee hassle-free setup and operation. The GL530MG provides a comprehensive view of assets' movements and activities, enabling optimization, reduced downtime, and increased productivity. "I am pleased that our GL530MG has been recognized as Asset Tracking product of the year by the IoT Evolution," said Manny Hernandez, Vice President of North America at Queclink Wireless. "This achievement drives us to produce sublime products and motivates us to continue our mission to shape the future of advanced asset tracking." "It is my pleasure to recognize Queclink with an IoT Evolution Asset Tracking Award for its continued innovation," said Carl Ford, Community Developer, IoT Evolution World. "As a leader in this rapidly evolving industry, I look forward to seeing Queclink's future successes." Earlier in May, Queclink has also been named winner of two honors in 2023 Globee Awards for Information Technology: the IT Solutions for Agriculture Award with its GB130MG, and the IT Solutions for Construction Award with its stolen asset recovery solution. While the advanced tracker GB130MG shows immense value to the agricultural market by providing crucial information ranging from fuel consumption to identifying maintenance requirements, the stolen asset recovery solution featuring dual trackers also offers timely reports and real-time alerts for abnormal activity that enables multi-layered protection against costly equipment theft suffered by the construction businesses. These awards acknowledge Queclink's excellence through the advanced, ground-breaking products, solutions, and services that the company provides, highlighting their remarkable contributions and commitment to driving innovation in the field. The company will continue to prioritize delivering top-quality products and actively engaging with customers to incorporate their feedback. Their focus will also remain on exploring and developing IoT solutions that cater to the evolving needs of the customers, the industry, and beyond. Photo – https://mma.prnewswire.com/media/2091777/Queclink_Receives_2023_IoT_Evolution_Asset_Tracking_Award.jpg  
View original content:https://www.prnewswire.co.uk/news-releases/queclinks-gl530mg-honored-for-excellent-innovation-in-burgeoning-iot-market-segment-301841171.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

Categorie
Adnkronos News

Giulia Tramontano, le verifiche sui video alla ricerca di complici

(Adnkronos) – Omicidio di Giulia Tramontano, i carabinieri del nucleo investigativo di Milano e i colleghi della compagnia di Rho stanno raccogliendo le immagini delle telecamere di videosorveglianza di Senago, il comune alle porte di Milano dove lo scorso sabato la donna è stata uccisa dal compagno Alessandro Impagnatiello. L'obiettivo – a quanto si apprende – è duplice: da un lato quello di verificare che il barman 30enne non abbia avuto complici e dall'altro ricostruire con esattezza gli spostamenti dell'uomo, che ha confessato di aver ucciso Giulia la sera dello scorso sabato all'interno del loro appartamento di Senago e di averne poi inscenato e denunciato la scomparsa, mentre tentava di disfarsi del corpo, dandolo due volte alle fiamme e poi nascondendolo in garage, nel bagagliaio dell'auto e infine in un'intercapedine in un'area dismessa, dove su sua indicazione i carabinieri lo hanno trovato nella notte tra mercoledì e giovedì.  
Le immagini potranno quindi chiarire se aderisca al vero il racconto di Impagnatiello, che – scrivono l’aggiunta Letizia Mannella e la pm Alessia Menegazzo nel decreto di fermo – “ha dimostrato di essere in grado di mentire ripetutamente e di cambiare più volte versione dei fatti”. Il 30enne ha sostenuto anche questa mattina durante l'interrogatorio di convalida del fermo davanti al gip Angela Minerva di ucciso Giulia e di averne occultato il cadavere da solo, senza l'aiuto di complici.  —cronacawebinfo@adnkronos.com (Web Info)

Categorie
Adnkronos News

Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation Results at ASCO 2023 Annual Meeting

(Adnkronos) – An oral presentation titled "Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results" will be provided by Howard Safran, MD during the ASCO Developmental Therapeutics – Immunotherapy Session on June 4th. WALTHAM, Mass., June 2, 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced an oral presentation of Phase 1 DF1001 Monotherapy Dose Escalation Results scheduled on Sunday June 4, from 11:45 – 11:57 a.m. The presentation will be in the Arie Crown Theater at the McCormick Place Convention Center in Chicago for the ASCO 2023 Annual Meeting. The presentation, ASCO Abstract 2508, will be given by Howard P. Safran, MD, Chief of Hematology/Oncology at the Lifespan Cancer Institute and Medical Director for the Brown University Oncology Group. Dr. Safran is a lead investigator on the Phase 1/2 clinical trial for the DF1001 TriNKET®, a first-in-human study exploring the safety, tolerability, and preliminary biological and clinical activity of DF1001, an immunotherapy targeting HER2 in patients with advanced solid tumors. "We look forward to presenting our DF1001 Phase 1 study results at ASCO," said Joseph Eid, MD, President of Research and Development at Dragonfly Therapeutics. DF1001 is a first-in-class immune modulating TriNKET targeting HER2 that drives immune activation in solid tumors. DF1001 is also being evaluated in combination with nivolumab or nab paclitaxel. Clinical trial sites are open in the U.S., France, Belgium, Denmark and The Netherlands. Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04143711). About DF1001DF1001 is an investigational first-in-class drug candidate that targets natural killer (NK) cells and T-cell activation signals to co-activating NK receptors, where NKG2D and CD16 co-stimulation yields distinctive and potent NK cell activation. DF1001 is being evaluated in adult patients for the treatment of advanced solid HER2-positive tumors. DF1001 was discovered and developed using Dragonfly's TriNKET Platform. DF1001 has the potential to stimulate effective anti-tumor immunity in patients who are not eligible or not adequately responding to current therapies. DF1001 is the most advanced in a pipeline of TriNKETs that Dragonfly is developing to address high unmet needs for patients across a broad range of disease areas. About DragonflyDragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing therapies that use its novel bispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly-owned clinical assets and multiple assets in the clinic with partners, Dragonfly has a deep pipeline of wholly-owned preclinical candidates developed using its proprietary platforms as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb, in a broad range of disease areas.  For more information visit: www.dragonflytx.com
https://www.linkedin.com/company/dragonfly-therapeutics-inc./
https://twitter.com/dragonflytx  DRAGONFLY MEDIA CONTACT:Anne Deconinck | anne@dragonflytx.com  Logo – https://mma.prnewswire.com/media/390962/4066598/Dragonfly_Therapeutics_Inc_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/dragonfly-therapeutics-to-present-phase-1-df1001-monotherapy-dose-escalation-results-at-asco-2023-annual-meeting-301840938.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

Categorie
Adnkronos News

Incidente a Grosseto, auto fuori strada: muore 48enne

(Adnkronos) –
Finisce fuori strada con l'auto e muore: il corpo senza vita di un uomo di 48 anni è stato trovato, questa mattina, alcune ore dopo l'incidente stradale che sarebbe avvenuto in maniera autonoma. Il sinistro si è verificato nel comune di Grosseto, lungo la strada provinciale del Padule, poco dopo l'ingresso dell'aeroporto militare, in direzione di Castiglione della Pescaia.  I soccorsi, secondo quanto si è appreso, sarebbero stati attivati intorno alle 9.15, quando in via Castiglionese si sono portati i mezzi del 118, con l'attivazione del Pegaso 2, la polizia di Stato, i carabinieri, e i vigili del fuoco. Ma per il conducente uscito fuori strada non c'è stato niente da fare perché già morto, forse sul colpo, un paio di ore prima, verso le 7 come ipotizzano le forze dell'ordine che hanno condotto i primi accertamenti.  Il 48enne alla guida dell'auto era un dipendente civile del Ministero della Difesa, in servizio presso il comando provinciale dei carabinieri di Grosseto. L'uomo, originario di Taranto, dove era nato nel 1975, fino al 2019 è stato carabiniere in servizio a bordo della motovedetta dell'Arma a Castiglione della Pescaia. —cronacawebinfo@adnkronos.com (Web Info)

Categorie
Adnkronos News

Giordania, anche Renzi al royal wedding: “Fuga di qualche ora con Agnese”

(Adnkronos) – "In Giordania per il #RoyalWedding. Fuga di qualche ora con Agnese immersi nella bellezza di Petra". Lo scrive su Twitter il leader di Italia Viva Matteo Renzi postando una foto con la moglie scattata davanti alle celebri rovine di Petra.  Il principe ereditario di Giordania Al Hussein bin Abdullah e l'architetta saudita Rajwa Al Saif si sono sposati ieri al Palazzo Zahran di Amman, riportano i media arabi che hanno seguito in diretta la cerimonia religiosa e che hanno filmato le promesse di matrimonio, lo scambio delle fedi nuziali e la firma del contratto. Al-Saif sarà ora conosciuta come Sua Altezza reale la principessa ereditaria di Giordania e, quando il principe ereditario salirà al trono, sarà la regina Rajwa. La cerimonia, che si è svolta nello stesso palazzo dove re Abdullah II e la regina Rania si sono sposati nel 1993, è stata seguita in presenza da circa 140 ospiti, tra cui membri della famiglia reale hashemita, reali invitati e capi di stato. Tra gli invitati anche la first lady Usa Jill Biden e il principe e la principessa del Galles William e Kate.  —politicawebinfo@adnkronos.com (Web Info)

Categorie
Adnkronos News

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

(Adnkronos) – SAN DIEGO and SAN JOSE, Calif., June 2, 2023 /PRNewswire/ — Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics' NGS platforms. The territory is worldwide, and the field is oncology and cancer research. Under the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. These biomarker tests can be used for upfront screening of research specimens, as well as for surveillance, monitoring, and detection of measurable residual disease (MRD) in a clinical research setting. The biomarker tests will initially be released worldwide as Research Use Only (RUO). Additionally, development of CLIA/CAP-validated tests within Invivoscribe's worldwide network of clinical LabPMM laboratories in the US, Europe, Japan, and China is planned. Long-term plans include expansion of the relationship into clinical studies and regulatory submissions worldwide to support commercialization of in vitro diagnostic (IVD) testing products. "We are thrilled to be partnered with Complete Genomics worldwide, as they offer NGS platforms with excellent performance metrics, and lower cost systems and reagents vs. those provided by the other NGS providers," said Jeffrey Miller, CEO and CSO at Invivoscribe. "Our LeukoStrat® CDx FLT3 Mutation Assay is an internationally standardized, FDA and IVDR approved PCR-based capillary test that has proven invaluable as a companion diagnostic for three approved FLT3 targeted therapies. Though it is available worldwide both as a kit and as a testing service in our LabPMM laboratories, in order to study and monitor the level of AML disease following the identification of FLT3-positive AML subjects, we also need to provide a highly sensitive NGS-based FLT3 test. So, among the first tests we will develop and launch as RUO kits on the Complete Genomics DNBSEQ-G99 platform is our FLT3-ITD MRD test, which is currently being offered as a CLIA/CAP testing service in our LabPMM laboratories on another NGS platform and is being used by investigators to monitor and track residual disease in AML subjects in a clinical research setting." "We are thrilled to be partnering with Invivoscribe, a proven developer of high-quality tests to deliver a complete workflow solution," Yongwei Zhang, CEO of Complete Genomics. Tests being developed for the Complete Genomics DNBSEQ-G99 platform will include both screening and highly sensitive MRD monitoring research for the full range of hematologic malignancies, including acute myeloid leukemia (AML). AML is a blood cancer that affects the blood and bone marrow and is characterized by the rapid growth of abnormal white blood cells.1 AML has the lowest 5-year survival rate (31.7%) among people diagnosed with leukemia.2  About 25% of AML patients have a FLT3-ITD mutation, which contributes to the growth and survival of cancer cells and is associated with a poor prognosis.3  About InvivoscribeInvivoscribe is a global, vertically-integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For nearly thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, bioinformatics tools, and services to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies, providing expertise in diagnostic development and regulatory submission through commercialization of companion diagnostics. For additional information, please visit www.invivoscribe.com. About Complete GenomicsComplete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput sequencing technology development since its inception in 2005. Our products have powered over 4,000 publications across a wide array of applications. To learn more, visit www.completegenomics.com. 1 https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/introduction2 https://seer.cancer.gov/statfacts/html/amyl.html 3 Daver N et al. Leukemia (2019) 33:299–312.  Logo – https://mma.prnewswire.com/media/1019746/Invivoscribe_Logo.jpg
 
View original content:https://www.prnewswire.co.uk/news-releases/invivoscribe-partners-with-complete-genomics-to-develop-and-commercialize-biomarker-tests-for-oncology-and-cancer-research-301840836.html
 

 —immediapress/pr-newswirewebinfo@adnkronos.com (Web Info)

Categorie
Adnkronos News

Ucraina, sesta ondata di attacchi a Kiev: abbattuti missili e droni

(Adnkronos) – La difesa aerea ucraina ha abbattuto oltre 30 missili e droni su Kiev la notte scorsa in quella che è stata la sesta ondata di attacchi russi alla capitale ucraina in sei giorni. Lo rende noto Serhiy Popko, capo dell'amministrazione militare di Kiev, su Telegram. Secondo quanto reso noto dall'ufficio del procuratore generale della capitale, due persone – un bambino di 11 anni ed un uomo di 68 – sono rimaste ferite dalla caduta di detriti dopo che la difesa aerea ha respinto l'attacco russo.  Nel dettaglio, le forze ucraine hanno abbattuto 15 missili cruise e 21 droni di fabbricazione iraniana Shahed. Il governatore russo di Belgorod ha intanto reso noto che due donne sono rimaste uccise e due persone sono state ferite quando le forze ucraine hanno bombardato una strada nella località Maslova Pristan vicino al confine ucraino. "Frammenti di ordigni hanno colpito le auto che passavano, le due donne erano a bordo di un'auto e sono morte sul colpo", ha detto il governatore Vyacheslav Gladkov. Altri governatori russi hanno denunciato oggi attacchi nelle loro regioni. Vasily Anokhin, governatore della regione di Smolensk, afferma che due droni hanno attaccato installazioni energetiche nei villaggi di Peresna e Divasy. Non vi sarebbero vittime o danni importanti, aggiunge.  Due villaggi di un'altra regione confinante con l'Ucraina, Bryansk, sarebbero stati bombardati nella notte, secondo quanto riporta il governatore Aleksandr Bogomaz puntando il dito contro le forze armate ucraine. Vi sarebbero stati incendi in due case, ma non ci sarebbero vittime. Né Kiev né Mosca hanno chiuso "in modo fermo" la porta a negoziati per la fine del conflitto, ha assicurato intanto l'inviato cinese per gli affari euroasiatici, Li Hui, che nei giorni scorsi è stato in missione in Russia, Ucraina e altri Paesi europei e oggi ha tenuto una conferenza stampa per riferire degli esiti. "Il rischio di escalation della guerra russo-ucraina è ancora alto", ha ammesso Li, esortando le parti a prendere misure concrete "per raffreddare la situazione", intanto garantendo la sicurezza degli impianti nucleari. —internazionale/esteriwebinfo@adnkronos.com (Web Info)